Skip to Content


Our Services and Partners


LIFE LENGTH

Life Length is the world's leading diagnostic biotech company owing an intellectual property and a proprietary platform technology, based on the measurement of telomere variables and the related trials for aging and age-related diseases.

Based in Madrid, Life Length is the most advanced accredited clinical laboratory holding an Operating License from the Spanish Agency for Medicines and Health Products, and being the only US federal laboratory in Spain.

HealthTAV® monitors the aging process. This test evaluates thxe extent to which aging is affected by lifestyle and therapeutic interventions. It also analyzes effectiveness of personalized wellness programs and compliance to them.

HealthTAV® uses our patented TAT® (Telomere Analysis Technology), the worldwide most accurate tool for the measurement of telomere length and the determination of the multiple associated variables.

ProsTAV a new telomere - based biomarker for the early diagnosis of prostate cancer. ProsTAV helps reduce by 33% the need for unnecessary biopsies.

www.lifelength.com

Tempus

Focus: AI-Driven Comprehensive Molecular Profiling

Tempus pairs one of the largest libraries of clinical and molecular data in oncology with an AI-powered platform built to turn that data into decisions at the point of care — not months later, when the window to act has narrowed.

• xT  — FDA-approved tumor tissue profiling covering one of the largest reported gene panels available, mapped directly to NCCN Guidelines® and MSK's OncoKB™ so findings translate straight into treatment options.

• xF / xF+ liquid biopsy — a 105-gene blood-based panel that catches actionable mutations tissue biopsy alone can miss; in published NSCLC data.

• xR RNA sequencing — layered alongside DNA profiling to surface fusions and expression changes DNA-only testing overlooks.

One blood draw or biopsy. A full genomic picture. Answers physicians can act on immediately.

https://www.tempus.com/

NEOSCREEN

Focus: Genetic Testing

Neoscreen Ltd. is an ISO 15189 and 17025 accredited laboratory, for performing molecular diagnostic tests, that has specialized in Clinical Genetic tests since 2007.


Its expertise includes Carrier Screening, Cancer Predisposition, Expanded Newborn Screening, Whole Exome and Whole Genome Sequencing.


Neoscreen long standing expertise in genetic testing has been added up to its flexibility to adapt to frequent changes and needs from the medical community to updated panels and tests to improve diagnosis.


www.neoscreen.online/en

GENPATH

Focus: Urology

GenPath Diagnostics, a division of Bioreference, offers comprehensive tests and services to help diagnosis and management. GenPath provides urologists with access to a suite of diagnostic testing for a variety of urologic conditions, including prostate cancer, bladder cancer, hereditary cancers, kidney stones, and sexually transmitted infections.

GenPath offers the 4Kscore® Test, a blood test combining four prostate-specific biomarkers with important clinical factors. This tests provides a man's risk for aggressive prostate cancer if a biopsy were to be performed, and offers results that should be considered in the shared decision-making process.

www.genpathdiagnostics.com

SMART CELLS INTERNATIONAL SCI

Focus: Stem Cells Cord Blood Banking


Securing umbilical cord blood during childbirth may provide your child access to potential stem cell-based therapies in the future. Umbilical cord blood stem cells, similar to bone marrow stem cells, are used in the treatment of nearly 80 severe oncological and hematological diseases. Research is ongoing to explore their use in autoimmune and neurological disorders.


Smart Cells International (SCI) is the UK's first private bank for cord blood and cord tissue storage. It is licensed by the Human Tissue Authority (HTA) and has been operating since 2000. Today, SCI is part of FamiCord Group, the largest cord blood bank in Europe and the third largest cord blood bank in the world with more than 700,000 units collected globally.


SCI has so far released more samples for clinical use than any other private storage company in the UK with a 100 per cent success rate. These units have been used by patients all around the world to treat a range of conditions including Cerebral Palsy, Thalassemia, Sickle-cell anemia, Leukemia, and HSV Encephalitis.


Leading the way by using state of the art technology, Smart Cells International is the most innovative company in the field. SCI uses its own laboratories for processing collected samples using Biosafe Sepax equipment for automated volume reduction of cord blood as this is the preferred method for all public banks in the United Kingdom and around the world. SCI is located near Heathrow airport in London, with 12 other laboratories in Europe. Moreover, SCI has the best credit score rating when compared to other banks in the UK.


STEM CELLS: storing the stem cells of life

Smart Cells Baby - Stem cells for life

Smart Cells - Baby

www.smartcells.com

PATHGROUP

Focus: Hematology testing

PathGroup is committed to providing diagnostic expertise, precision technologies and innovative services and relationships — all to offer clinician partners personalized information for targeted therapies that lead to the best possible patient's outcome.

Led by recognized experts in the field of molecular diagnostics and bioinformatics, PathGroup works with leading individual and contract research partners in developing platforms for improved molecular intelligence. PathGroup molecular diagnostics facility includes a dedicated CLIA validation laboratory to accelerate delivery of new tests and modalities to the physicians and the patients they treat. The portfolio includes several Hematology panels in addition to a large panel of genes tested by Immunohistochemistry (IHC) and NGS, with a comprehensive report that helps guide clinicians toward beneficial therapies for the patient.

www.pathgroup.com

NATERA

Focus: cfDNA testing in Oncology and women's health

Natera is a global leader in cell-free DNA (cfDNA) testing, with diagnostic solutions across Oncology and Women's health.

Oncology: Signatera MRD

Signatera™ is a personalized, tumor-informed circulating tumor DNA (ctDNA) assay designed to assess Molecular Residual Disease (MRD) and monitor cancer recurrence.

Depending on the clinical context, Signatera™ may be used across most cancer types to:

          • Assess molecular residual disease after treatment.

          • Support decisions regarding adjuvant and Neoadjuvant therapy.

          • Monitor for molecular evidence of recurrence.

          • Evaluate treatment response in selected patients.

Backed by 100+ peer-reviewed studies, Signatera is now recognized by NCCN as a strong prognostic, risk marker for colon and rectal cancer, and specifically cited in its Merkel cell carcinoma guidelines. Covered by US Medicare across colorectal, breast, bladder, ovarian and lung cancer, plus pan-cancer immunotherapy monitoring. Signatera has also been validated lately for monitoring of Lymphoma. Today, Signatera is one of the most validated MRD tests available on the market.

https://www.natera.com/oncology/

Women's Health: Panorama and Horizon

Panorama® is a non-invasive prenatal screening test based on cfDNA in maternal blood that evaluates the risk of selected abnormal chromosomal conditions affecting the fetus.

It can be performed as early as 9 weeks of pregnancy onwards and uses SNP-based technology to distinguish maternal and fetal DNA providing detailed and accurate screening information.

In addition to trisomies 21, 13 and 18, Panorama can be extended to a series of common microdeletions responsible for several abnormal fetal conditions. The test can also be combined to fetus Rhesus determination, a very useful test in Rhesus-negative mothers.


Horizon: a comprehensive, actionable carrier screening. Horizon helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either during preconception (ideally) or during pregnancy.

Brochure NATERA

www.natera.com

AGENDIA

Focus: Precision Oncology for Breast Cancer

Agendia is a precision oncology company dedicated entirely to breast cancer. Its genomic tests interrogate the tumor biology directly, rather than relying only on traditional clinical and histopathological factors like age, tumor grade, and hormone receptor status — helping physicians avoid both under- and over-treatment.

MammaPrint® + BluePrint®

• Both results are available in about 6 business days from a single tissue sample.

• MammaPrint is an FDA-cleared and CE-marked risk stratification test, validated by the MINDACT study, a prospective and randomized clinical trial published in NEJM in 2016 and backed by several other peer-reviewed studies on thousands of patientsBluePrint adds molecular subtyping, showing how a tumor is likely to respond to treatment

• Recommended by international guidelines including ESMO, St. Gallen, ASCO, and NCCN for its prognostic and predictive value in all early stage Breast Cancer categories.

• The two tests together help answer two critical questions: 

What are the chances her cancer returns ?

What type of cancer am I dealing with ?


Brochure

www.agendia.com